LONDON and CAMBRIDGE, MA--(Marketwire - April 27, 2009) - InforSense Ltd., the
leading provider of next generation business and scientific intelligence
solutions, today announced that Celera Corporation, a healthcare business
delivering personalized disease management through a combination of
products and services incorporating proprietary discoveries, is using
InforSense to integrate internal molecular and public data sources to
accelerate the successful identification of genetic markers, such as those
Celera has reported for increased risk of Coronary Heart Disease (CHD).
The InforSense Translational Research Solution enables Celera to
accelerate and automate many aspects of experimental data analysis and
molecular annotation saving considerable time and effort. Celera and
InforSense have developed a long-term relationship that covers the use of
InforSense's Translational Research Solution to glean insight from
available data and inform follow up studies for diagnostic markers of
disease at Celera. These collaborative efforts complement and extend the
pioneering informatics efforts of both companies independently.
InforSense has provided Celera with a configurable, scientist-friendly
solution for translational research to support clinical data browsing,
automated integration and analysis of enzyme linked immunoassay (ELISA),
single nucleotide polymorphisms (SNPs) and other experimental proprietary
and public data. By building bioinformatic queries and statistical analysis
workflows, waiting times for scientists are significantly reduced and
further investigation can focus on innovative developments saving valuable
time and reducing costs. Celera used the knowledge gained from the
identification of the gene variant in KIF6 that predicts CHD, to create and
assemble key workflows, which streamline the overall process and provide
for future acceleration of discovery efforts of this and other markers.
"A commercialization focus at Celera is developing advanced diagnostic
biomarkers to detect, predict, characterize, monitor and select treatment
for disease. We wanted to empower our scientists to be able to access and
analyze a variety of orthologous clinical and experimental data to support
biomarker discovery and InforSense has provided us with the means to do
this," said John Sninsky, Vice President Research, Celera. "Fundamental
contributions were made to disease understanding through InforSense
solutions prioritizing literature queries and informing functional studies.
Without these informatics tools, follow up studies of gene variants would
be delayed."
"Celera is leading the way in developing new diagnostic biomarkers and we
are delighted to be working with them in this vital field," said Jonathan
Sheldon, Chief Science Officer, InforSense. "We are seeing increasing
consistency and repetition in the market place for our productized approach
to translational research informatics, which is increasingly being adopted
in Pharmaceutical, Diagnostics, and Biotech companies as well as leading
medical institutes. Not only does InforSense accelerate the biomarker
discovery process, it slashes cost as well."
David Ross, Director of Computational Biology, Celera, will be presenting
his findings on this project at the BioIT World Conference 2009. His talk
is entitled "Assessment of the function and potential clinical relevance of
gene variants from genome wide association studies using workflow-driven
bioinformatics."
About InforSense Translational Research Solution
The InforSense Translational Research Solution provides a powerful and
flexible framework to integrate and analyze clinical, patient specimen and
experimental data for translational research. The solution builds on
InforSense's expertise developing translational research analytics
applications for the world's leading research institutes. It incorporates
the power of the InforSense platform with expertise in micro-array analysis, cohort identification and
clinical decision support and automated QC and analysis of Genome Wide
Association Studies. InforSense text mining enables experimental results to
form the basis of discovery in scientific literature and enables disease
associations and other findings to be quickly established. InforSense
Document Explorer is an ontology powered document viewer that is used to
deliver the results of text mining to end users in an easy to use format.
These tools enables translational analysis to be quickly implemented out of
the box with minimum configuration, but enables best practice analytical
workflows to be developed and modified by internal teams, providing the
flexibility to manage this evolving research field. Features include:
-- Easy integration of data sets - All clinical, patient sample and
experimental data can be integrated into a consistent informatics platform
improving decision making by incorporating all available data
-- Simple web interface - Study designers and scientists can query and
analyze the data through simple web interfaces produced by expert
developers and statisticians, removing bottlenecks in accessing the data
-- Flexible platform - Workflows can be quickly developed and evolved
enabling best practices to be flexibly optimized rather than needing to re-
implement systems with each iteration
-- Advanced and scalable analytics - Proven scalability of the InforSense
5.0 platform allows large data sets to analyzed using a wide variety of pre-
integrated tools such as R and SAS providing a future proof environment.
About InforSense
InforSense delivers fast answers to complex questions in business,
healthcare and life science. InforSense's next generation business and
scientific intelligence solutions provide ROI in days, not months. Designed
to handle today's complex business environments, where traditional BI
products often fall short, the InforSense platform has the power and
agility to integrate, analyze and visualize any data in any way. Around the
world, leading pharmaceutical, biotechnology, consumer goods, healthcare,
financial services, manufacturing and communications companies rely on
InforSense. The company is privately held, with European headquarters in
London, UK and North American headquarters in Cambridge, Massachusetts. For
more information, visit www.inforsense.com and on Twitter at
www.twitter.com/inforsense
InforSense and the InforSense logo are registered trademarks of InforSense
Limited. All rights reserved. All other trademarks mentioned in this
document are the property of their respective owners.
